Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 257
    records per page




    Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety—Particularities in the Context of COVID-19 MESHD

    Authors: Ana Miruna Dragoi; Ioana Radulescu; Anca Lucia Pop; Bogdana Adriana Năsui; Valentin Varlas; Simona Trifu

    id:10.20944/preprints202009.0724.v2 Date: 2020-11-09 Source: Preprints.org

    Background: Clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia MESHD schizophrenia HP (TRS) in adults TRANS and is underused. Objective: to examine the most recent CLZ data on (a) side effects concerning (b) recent pharmacological mechanisms, (c) therapy benefits, and (d) the particularities of the COVID-19 MESHD pandemic. Data sources: a search was performed in two databases (PubMed and Web of Science) using the specific keywords "clozapine" and " schizophrenia MESHD schizophrenia HP," "side effects," " agranulocytosis HP agranulocytosis MESHD," "TRS," or " bipolar affective disorder MESHD bipolar affective disorder HP ( BAF MESHD)" for the last ten years. Study eligibility criteria: clinical trials on adults TRANS with acute symptoms of schizophrenia HP schizophrenia MESHD or related disorders. Results: We selected 37 studies, randomized controlled trials (RCTs), and clinical case series (CCS), centered on six main topics in the search area: (a) CLZ in schizophrenia HP schizophrenia MESHD, (b) CLZ in bipolar disorder MESHD, (c) side effects during the clozapine therapy, (d) CLZ in pregnancy, (e) CLZ in early-onset schizophrenia HP schizophrenia MESHD, and (f) CLZ therapy and COVID-19 MESHD infection. Limitations: We considered RCTs and CCS from two databases, limited to the search topics. Conclusions and implications of key findings: (a) Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available; the genetic vulnerability postulates predictors of adverse reactions' severity; patients with a lower genetic risk could have less frequent hematological monitoring; (b) CLZ-associated risk of pulmonary embolism HP pulmonary embolism MESHD imposes prophylactic measures for venous thromboembolism MESHD thromboembolism HP; (c) convulsive MESHD episodes are not an indication for stopping treatment; the plasma SERO concentration of clozapine is a better side effect predictor than the dosage; (d) COVID-19 MESHD infection may enhance clozapine toxicity MESHD, generating an increased risk of pneumonia HP pneumonia MESHD. Therapy must be continued with proper monitoring of the white blood SERO count, and the clozapine dose decreased by half until three days after the fever HP fever MESHD breaks; psychiatrists and healthcare providers must act together. Background: Clozapine (CLZ) use is precarious due to its neurological, cardiovascular, and hematological side effects; however, it is the gold standard in therapy-resistant schizophrenia HP schizophrenia MESHD (TRS) in adults TRANS and is underused. Objective: to examine the most recent CLZ data on (a) side effects concerning (b) recent pharmacological mechanisms, (c) therapy benefits, and (d) the particularities of the COVID-19 MESHD pandemic. Data sources: a search was performed in two databases (PubMed and Web of Science) using the specific keywords "clozapine" and " schizophrenia HP schizophrenia MESHD," "side effects," " agranulocytosis MESHD agranulocytosis HP," "TRS," or " bipolar affective disorder HP bipolar affective disorder MESHD ( BAF MESHD)" for the last ten years. Study eligibility criteria: clinical trials on adults TRANS with acute symptoms of schizophrenia HP schizophrenia MESHD or related disorders. Results: We selected 37 studies, randomized controlled trials (RCTs), and clinical case series (CCS), centered on six main topics in the search area: (a) CLZ in schizophrenia MESHD schizophrenia HP, (b) CLZ in bipolar disorder MESHD, (c) side effects during the clozapine therapy, (d) CLZ in pregnancy, (e) CLZ in early-onset schizophrenia MESHD schizophrenia HP, and (f) CLZ therapy and COVID-19 MESHD infection. Limitations: We considered RCTs and CCS from two databases, limited to the search topics. Conclusions and implications of key findings: (a) Clozapine doses should be personalized for each patient based on pharmacogenetics testing when available; the genetic vulnerability postulates predictors of adverse reactions' severity; patients with a lower genetic risk could have less frequent hematological monitoring; (b) CLZ-associated risk of pulmonary embolism HP pulmonary embolism MESHD imposes prophylactic measures for venous thromboembolism MESHD thromboembolism HP; (c) convulsive MESHD episodes are not an indication for stopping treatment; the plasma SERO concentration of clozapine is a better side effect predictor than the dosage; (d) COVID-19 MESHD infection may enhance clozapine toxicity MESHD, generating an increased risk of pneumonia HP pneumonia MESHD. Therapy must be continued with proper monitoring of the white blood SERO count, and the clozapine dose decreased by half until three days after the fever HP fever MESHD breaks; psychiatrists and healthcare providers must act together.

    The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection MESHD by associating with L-SIGN and DC-SIGN

    Authors: Wai Tuck Soh; Yafei Liu; Emi E Nakayama; Chikako Ono; Shiho Torii; Hironori Nakagami; Yoshiharu Matsuura; Tatsuo Shioda; Hisashi Arase; Reid Simon; Ivan Grishagin; Laura Brovold; Ewy A Mathé; Matthew D Hall; Samuel G Michael; Alexander G Godfrey; Jordi Mestres; Lars J Jensen; Tudor I Oprea; Isabel Crooker; Sara Y Del Valle; Guido Espana; Geoffrey Fairchild; Richard C Gerkin; Timothy C Germann; Quanquan Gu; Xiangyang Guan; Lihong Guo; Gregory R Hart; Thomas J Hladish; Nathaniel Hupert; Daniel Janies; Cliff C Kerr; Daniel J Klein; Eili Klein; Gary Lin; Carrie Manore; Lauren Ancel Meyers; John Mittler; Kunpeng Mu; Rafael C NUNez; Rachel Oidtman; Remy Pasco; Ana Pastore y Piontti Pastore y Piontti; Rajib Paul; Carl AB Pearson; Dianela Perdomo; T Alex Perkins; Kelly Pierce; Alexander N Pillai; Rosalyn Cherie Rael; Katherine Rosenfeld; Chrysm Watson Ross; Julie A Spencer; Arlin B Stoltzfus; Kok Ben Toh; Shashaank Vattikuti; Alessandro Vespignani; Lingxiao Wang; Lisa White; Pan Xu; Yupeng Yang; Osman N Yogurtcu; Weitong Zhang; Yanting Zhao; Difan Zou; Matthew Ferrari; David Pannell; Michael Tildesley; Jack Seifarth; Elyse Johnson; Matthew Biggerstaff; Michael Johansson; Rachel B Slayton; John Levander; Jeff Stazer; Jessica Salermo; Michael C Runge

    doi:10.1101/2020.11.05.369264 Date: 2020-11-05 Source: bioRxiv

    The widespread occurrence of SARS-CoV-2 has had a profound effect on society and a vaccine is currently being developed. Angiotensin-converting enzyme 2 (ACE2) is the primary host cell receptor that interacts with the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Although pneumonia MESHD pneumonia HP is the main symptom in severe cases of SARS-CoV-2 infection MESHD, the expression levels of ACE2 in the lung is low, suggesting the presence of another receptor for the spike protein. In order to identify the additional receptors for the spike protein, we screened a receptor for the SARS-CoV-2 spike protein from the lung cDNA library. We cloned L-SIGN as a specific receptor for the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. The RBD of the spike protein did not bind to L-SIGN. In addition, not only L-SIGN but also DC-SIGN, a closely related C-type lectin receptor to L-SIGN, bound to the NTD of the SARS-CoV-2 spike protein. Importantly, cells expressing L-SIGN and DC-SIGN were both infected by SARS-CoV-2. Furthermore, L-SIGN and DC-SIGN induced membrane fusion by associating with the SARS-CoV-2 spike protein. Serum SERO antibodies SERO from infected patients and a patient-derived monoclonal antibody SERO against NTD inhibited SARS-CoV-2 infection of L-SIGN MESHD or DC-SIGN expressing cells. Our results highlight the important role of NTD in SARS-CoV-2 dissemination through L-SIGN and DC-SIGN and the significance of having anti-NTD neutralizing antibodies SERO in antibody SERO-based therapeutics.

    Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 MESHD by Upregulating Hyaluronan via NamiRNA-Enhancer Network

    Authors: Wei Li; Shuai Yang; Peng Xu; Dapeng Zhang; Ying Tong; Lu Chen; Ben Jia; Ang Li; Daoping Ru; Baolong Zhang; Mengxing Liu; Cheng Lian; Cancan Chen; Weihui Fu; Songhua Yuan; Xiaoguang Ren; Ying Liang; Zhicong Yang; Wenxuan Li; Shaoxuan Wang; Xiaoyan Zhang; Hongzhou Lu; Jianqing Xu; Hailing Wang; Wenqiang Yu; Vattipally B Sreenu; Jay Nix; Ruth F Jarrett; Martina Beltramello; Kyriaki Nomikou; Matteo Pizzuto; Lily Tong; Elisabetta Cameroni; Natasha Johnson; Arthur Wickenhagen; Alessandro Ceschi; Daniel Mair; Paolo Ferrari; Katherine Smollett; Federica Sallusto; Stephen Carmichael; Christian Garzoni; Jenna Nichols; Massimo Galli; Joseph Hughes; Agostino Riva; Antonia Ho; Peter JM Openshaw; Kenneth Baillie; - The ISARIC4C Investigators; - COVID-19 Genomics UK (COG-UK) consortium; Suzannah J Rihn; Samantha J Lycett; Herbert W Virgin; Amalio Telenti; Davide Corti; David L Robertson; Gyorgy Snell; Lingxiao Wang; Lisa White; Pan Xu; Yupeng Yang; Osman N Yogurtcu; Weitong Zhang; Yanting Zhao; Difan Zou; Matthew Ferrari; David Pannell; Michael Tildesley; Jack Seifarth; Elyse Johnson; Matthew Biggerstaff; Michael Johansson; Rachel B Slayton; John Levander; Jeff Stazer; Jessica Salermo; Michael C Runge

    doi:10.1101/2020.11.04.361576 Date: 2020-11-05 Source: bioRxiv

    The COVID-19 MESHD pandemic is a widespread and deadly public health crisis. The pathogen SARS-CoV-2 replicates in the lower respiratory tract and causes fatal pneumonia MESHD pneumonia HP. Although tremendous efforts have been put into investigating the pathogeny of SARS-CoV-2, the underlying mechanism of how SARS-CoV-2 interacts with its host is largely unexplored. Here, by comparing the genomic sequences of SARS-CoV-2 and human, we identified five fully conserved elements in SARS-CoV-2 genome, which were termed as "human identical sequences ( HIS MESHD)". HIS MESHD are also recognized in both SARS-CoV MESHD and MERS-CoV genome. Meanwhile, HIS-SARS-CoV-2 are highly conserved in the primate. Mechanically, HIS-SARS-CoV-2 RNA directly binds to the targeted loci in human genome and further interacts with host enhancers to activate the expression of adjacent and distant genes, including cytokines gene and angiotensin converting enzyme II (ACE2), a well-known cell entry receptor of SARS-CoV-2, and hyaluronan synthase 2 (HAS2), which further increases hyaluronan formation. Noteworthily, hyaluronan level in plasma SERO of COVID-19 MESHD patients is tightly correlated with severity and high risk for acute respiratory distress syndrome MESHD respiratory distress HP syndrome ( ARDS MESHD) and may act as a predictor for the progression of COVID-19 MESHD. HIS antagomirs, which downregulate hyaluronan level effectively, and 4-Methylumbelliferone (MU), an inhibitor of hyaluronan synthesis, are potential drugs to relieve the ARDS MESHD related ground-glass pattern in lung for COVID-19 MESHD treatment. Our results revealed that unprecedented HIS elements of SARS-CoV-2 contribute to the cytokine storm and ARDS MESHD in COVID-19 MESHD patients. Thus, blocking HIS-involved activating processes or hyaluronan synthesis directly by 4-MU may be effective strategies to alleviate COVID-19 MESHD progression.

    Randomized controlled trial of convalescent plasma SERO therapy against standard therapy in patients with severe COVID-19 MESHD disease

    Authors: Manaf AlQahtani; Abdulkarim Abdulrahman; Abdulrahman AlMadani; Salman Yousif AlAli; Alaa Mahmood Al Zamrooni; Amal Hejab; Pearl Wasif; Ronan Conroy; Stephen Atkin; Sameer Otoom; Manal Abduljalil AlSayed; Rebecca Jane Cox; Nina Langeland

    doi:10.1101/2020.11.02.20224303 Date: 2020-11-04 Source: medRxiv

    Background. Convalescent plasma SERO (CP) therapy in COVID-19 MESHD disease has been suggested to improve clinical outcome in severe disease. This pilot study was designed to inform the design of a definitive phase 3 clinical trial. Methods. This was a prospective, interventional and randomized open label pilot trial involving 40 patients with COVID-19 MESHD who were requiring oxygen therapy and who had radiological evidence of pneumonia MESHD pneumonia HP. Twenty COVID-19 MESHD patients received two 200ml transfusions of convalescent patient CP over 24 hours were compared with 20 patients who received routine care alone. The primary outcome was the requirement for ventilation. The secondary outcomes were white blood SERO cell count, lactate dehydrogenase (LDH), C-reactive protein (CRP), Troponin, Ferritin, D-Dimer, procalcitonin, mortality rate at 28 days. Results. The CP group were a higher risk group with higher ferritin levels (p<0.05) though respiratory indices did not differ. The primary outcome measure (ventilation) was required in 6 controls and 4 patients on CP (risk ratio 0.67 95% CI 0.22 to 2.0, p=0.72); mean time on ventilation was 10.5 days in the control against 8.2 days in patients on CP (p=0.81). There were no differences in secondary measures at the end of the study. Two patients died in the control and one patient in the CP arm. Conclusion. There were no significant differences in the primary or secondary outcome measures between CP and standard therapy though fewer patients required ventilation and for a shorter period of time. The study showed that CP therapy appears to be safe and it is feasible to perform a definitive phase 3 clinical trial using this study protocol.

    Anakinra To Prevent Respiratory Failure MESHD Respiratory Failure HP In COVID-19 MESHD

    Authors: Evdoxia Kyriazopoulou; Periklis Panagopoulos; Simeon Metallidis; George Dalekos; Garyfallia Poulakou; Nikolaos Gatselis; Eleni Karakike; Maria Saridaki; Georgia Loli; Aggelos Stefos; Danai Prasianaki; Sarah Georgiadou; Olga Tsachouridou; Vasileios Petrakis; Konstantinos Tsiakos; Maria Kosmidou; Vassiliki Lygoura; Maria Dareioti; Haralampos Milionis; Ilias C Papanikolaou; Karolina Akinosoglou; Dimitra-Melia Myrodia; Areti Gravani; Aliki Stamou; Theologia Gkavogianni; Konstantina Katrini; Theodoros Marantos; Ioannis P Trontzas; Konstantinos Syrigos; Lukas Chatzis; Stamatios Chatzis; Nikolaos Vechlidis; Christina Avgoustou; Stamatios Chalvatzis; Miltiades Kyprianou; Jos WM van der Meer; jesper eugen-olsen; Mihai Netea; Evangelos Giamarellos-Bourboulis

    doi:10.1101/2020.10.28.20217455 Date: 2020-10-29 Source: medRxiv

    Introduction The management of pneumonia MESHD pneumonia HP caused by SARS-CoV-2 should rely on early recognition of the risk for progression to severe respiratory failure MESHD respiratory failure HP ( SRF MESHD) and its prevention. We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19 MESHD-assocated SRF. Methods In this open-label prospective trial, 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 MESHD pneumonia HP SARS-CoV-2 and suPAR levels [≥]6 g/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome was the incidence of SRF MESHD at day 14. Secondary outcomes were 30-day mortality, changes in sequential organ failure assessment (SOFA) score, of cytokine-stimulation pattern and of circulating inflammatory mediators. Equal number of propensity score-matched comparators for comorbidities, severity on admission and standard-of care (SOC) were studied. Results The incidence of SRF MESHD was 22.3% (95% CI, 16.0-30.2%) among anakinra-treated patients and 59.2% (95% CI, 50.6-67.3%; P: 4.6 x 10-8) among SOC comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46). 30-day mortality was 11.5% (95% CI, 7.1-18.2%) and 22.3% (95% CI, 16.0-30.2%) respectively (hazard ratio 0.49; 95% CI 0.25-0.97%; P: 0.041). Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum SERO IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score. Duration of stay at the intensive care unit and at hospital was shortened compared to the SOC group; the cost of hospitalization was decreased. Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF MESHD and restoration of the pro- /anti-inflammatory balance.

    Intravenous Mesenchymal Stem Cells in Extracorporeal Oxygenation Patients with Severe COVID-19 MESHD Acute Respiratory Distress Syndrome MESHD Respiratory Distress HP Syndrome

    Authors: Sunjay Kaushal; Aisha Khan; Kristopher Deatrick; Derek K Ng; Abigail Snyder; Aakash Shah; Lina V Caceres; Ketty Bacallao; Melania Bembea; Allen Everett; Jie Zhu; David Kaczorowski; Ronson Madathil; Ali Tabatabai; Geoffrey Rosenthal; Adriana Brooks; Bangon Longsomboon; Rachana Mishra; Progyaparamita Saha; Yvenie Desire; Russell Saltzman; Kim G Hankey; Sixto A Arias; Folusakin Ayoade; Jairo A. Tovar; Rejane Lamazares; Hayley B Gershengorn; Fontaine J Magali; Matthias Loebe; Kristin Mullins; Muthukumar Gunasekaran; Vela Karakeshishyan; Dushyantha T Jayaweera; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20122523 Date: 2020-10-20 Source: medRxiv

    Background: There is an ongoing critical need to improve therapeutic strategies for COVID-19 MESHD pneumonia MESHD pneumonia HP, particularly in the most severely affected patients. Adult TRANS mesenchymal stem cell (MSC) infusions have the potential to benefit critically ill MESHD patients with acute respiratory syndrome SARS-COV-2 infection MESHD SARS-COV-2 infection MESHD, but clinical data supporting efficacy are lacking. Methods: We conducted a case-control study of critically ill MESHD patients with laboratory-confirmed COVID-19 MESHD, severe acute respiratory distress syndrome MESHD respiratory distress syndrome HP ( ARDS MESHD). To evaluate clinical responsiveness in the most critically ill patient we examined outcomes in a sub-group of those requiring extracorporeal membrane oxygenation (ECMO) support. Patients (n=9) were administered with up to 3 infusions of intravenous (IV) MSCs and compared to a local ECMO control group (n=31). The primary outcome was safety, and the secondary outcomes were all-cause mortality (or rate of hospital discharge), cytokine levels, and viral clearance. Findings: MSC infusions (12 patients) were well tolerated and no side effects occurred. Of ECMO patients receiving MSC infusions, 2 out of 9 died (22.2%; 95%CI: 2.8%, 60.0%) compared with a mortality of 15 of 31 (48.4%; 95%CI: 30.2%, 66.9%; p = 0.25) in the ECMO control group. Isolated plasma SERO exosomes containing the SARS-COV-2 Spike protein decreased after MSC infusions between day 14 or 21 after administration (p=0.003 and p=0.005, respectively) and was associated with a decrease in COVID-19 MESHD IgG Spike protein titer at same time points (p = 0.006 and p=0.007, respectively). Control ECMO patients receiving convalescent plasma SERO did not clear COVID-19 MESHD IgG over the same time frame. Interpretation: Together these findings suggest that MSC IV infusion is well tolerated in patients with a broad range of severity including the most severe COVID-19 MESHD ARDS requiring ECMO. These data also raise the possibility that MSCs, in addition to exerting an immunomodulatory effect, contribute to viral clearance and strongly support the conduct of randomized placebo-controlled trial.

    Correlation between Chest CT Severity Scores and the Clinical Parameters of Adult TRANS Patients with COVID-19 MESHD pneumonia HP pneumonia MESHD

    Authors: Ghufran Saeed; Waqar Gaba; Asad Shah; Abeer Al Helali; Emadullah Raidullah; Ameirah Al Ali; Mohammed Elghazali; Deena Ahmed; Shaikha Al Kaabi; Safaa Almazrouei; Juan M Lavista Ferres; Jane Eddleston; Chris Brookes; Christopher Harrison; Weiqi Liu; Tianyi Liu; Jin-Wen Song; Liangliang Sun; Fan Yang; Xin Zhang; Bo Zhang; Ming Shi; Fanping Meng; Yanning Song; Yongpei Yu; Jiqiu Wen; Qi Li; Qing Mao; Markus Maeurer; Alimuddin Zumla; Chen Yao; Weifen Xie; Fu-Sheng Wang; Anthony Atala; Ali Ghodsizad; Joshua M Hare

    doi:10.1101/2020.10.15.20213058 Date: 2020-10-20 Source: medRxiv

    Purpose Our aim is to correlate the clinical condition of patients with COVID-19 MESHD infection with the 25 Point CT severity score by Chang et al (devised for assessment of ARDS in patients with SARS in 2005). Material and Methods Data of consecutive symptomatic patients who were suspected to have COVID-19 MESHD infection and presented to our hospital, was collected from March to April 2020. All patients underwent two consecutive RT-PCR tests and had a non-contrast HRCT scan done at presentation. From the original cohort of 1062 patients, 160 patients were excluded leaving a total number of 902 patients. Results The mean age TRANS was 44.2 +/- 11.9 years [85.3% males TRANS, 14.7 % females TRANS]. CT severity score found to be positively correlated with lymphopenia MESHD lymphopenia HP, increased serum SERO CRP, d-dimer and ferritin levels (p < 0.0001). The oxygen requirements as well as length of hospital stay were increasing with the increase of scan severity. Conclusion The 25-point CT severity score correlates well with the COVID-19 MESHD clinical severity. Our data suggest that chest CT scoring system can aid in predicting COVID-19 MESHD disease outcome and significantly correlates with lab tests and oxygen requirements.

    Exclusion of bacterial co-infection MESHD in COVID-19 MESHD using baseline inflammatory markers and their response to antibiotics

    Authors: Claire Y Mason; Tanmay Kanitkar; Charlotte J Richardson; Marisa Lanzman; Zak Stone; Tabitha Mahungu; Damien Mack; Emmanuel Q Wey; Lucy Lamb; Indran Balakrishnan; Gabriele Pollara; Manish Pandey; Stephen Jolles; Jonathan Underwood; Eileen C Goodwin; Scott Hensley; Karen M Puopolo; Nicki Detlefsen; Andreas Lauritzen; Abraham George Smith; Marleen de Bruijne; Bulat Ibragimov; Jens Petersen; Martin Lillholm; Marie Helleberg; Benjamin Skov Kaas-Hansen; Jon Middleton; Stine Hasling Mogensen; Hans Christian Thorsen-Meyer; Anders Perner; Mikkel Bonde; Alexander Bonde; Akshay Pai; Mads Nielsen; Martin Sillesen

    doi:10.1101/2020.10.09.20199778 Date: 2020-10-11 Source: medRxiv

    Background COVID-19 MESHD is infrequently complicated by secondary bacterial infection MESHD, but nevertheless antibiotic prescriptions are common. We used community-acquired pneumonia MESHD pneumonia HP (CAP) as a benchmark to define the processes that occur in a bacterial pulmonary infection MESHD, and tested the hypothesis that baseline inflammatory markers and their response to antibiotic therapy could distinguish CAP from COVID-19 MESHD. Methods In patients admitted to Royal Free Hospital ( RFH MESHD) and Barnet Hospital (BH) we defined CAP by lobar consolidation on chest radiograph, and COVID-19 MESHD by SARS-CoV-2 detection by PCR. Data were derived from routine laboratory investigations. Results On admission all CAP MESHD and >90% COVID-19 MESHD patients received antibiotics. We identified 106 CAP and 619 COVID-19 MESHD patients at RFH MESHD. CAP was characterised by elevated white cell count (WCC) and C-reactive protein (CRP) compared to COVID-19 MESHD (median WCC 12.48 (IQR 8.2-15.3) vs 6.78 (IQR 5.2-9.5) x106 cells/ml and median CRP CRP 133.5 (IQR 65-221) vs 86 (IQR 42-160) mg/L). Blood SERO samples collected 48-72 hours into admission revealed decreasing CRP in CAP but not COVID-19 MESHD (CRP difference -33 (IQR -112 to +3.5) vs +15 (IQR -15 to +70) mg/L respectively). In the independent validation cohort (BH) consisting of 169 CAP and 181 COVID-19 MESHD patients, admission WCC >8.2x106 cells/ml or falling HP CRP MESHD during admission identified 95% of CAP cases, and predicted the absence of bacterial co-infection MESHD in 45% of COVID-19 MESHD patients. Conclusions We propose that in COVID-19 MESHD the absence of both elevated baseline WCC and antibiotic-related decrease in CRP can exclude bacterial co-infection MESHD and facilitate antibiotic stewardship efforts.

    EFFECT OF CONVALESCENT PLASMA SERO ON MORTALITY IN PATIENTS WITH COVID-19 MESHD PNEUMONIA HP

    Authors: Martin R Salazar; Soledad E Gonzalez; Lorena Regairaz; Noelia S Ferrando; Veronica Gonzalez; Patricia M Carrera; Laura Muñoz; Santiago A Pesci; Juan M Vidal; Nicolas Kreplak; Elisa Estenssoro; Harendra Guturu; Ahna R. Girshick; Kristin A. Rand; Eurie L. Hong; Catherine A. Ball; Stefan VANEL; Pierre MENDIHARAT; Klaudia PORTEN; William HENNEQUIN; Clair MILLS; Francisco LUQUERO

    doi:10.1101/2020.10.08.20202606 Date: 2020-10-09 Source: medRxiv

    Abstract Background Convalescent plasma SERO, widely utilized in viral infections that induce neutralizing antibodies SERO, has been proposed for COVID-19 MESHD, and preliminary evidence shows that it might have beneficial effect. Our objective was to compare epidemiological characteristics and outcomes between patients who received convalescent plasma SERO for COVID-19 MESHD and those who did not, admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic. Methods This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1, 2020, including unselected, consecutive adult TRANS patients with diagnosed COVID-19 MESHD, admitted to 215 hospitals with pneumonia HP pneumonia MESHD. Epidemiological and clinical variables were registered in the Provincial Hospital Bed Management System. Convalescent plasma SERO was supplied as part of a centralized, expanded access program. Results We analyzed 3,529 patients with pneumonia MESHD pneumonia HP, predominantly male TRANS, aged TRANS 62{+/-}17, with arterial hypertension HP hypertension MESHD and diabetes MESHD as main comorbidities; 51.4% were admitted to the ward, 27.1% to the Intensive Care Unit (ICU), and 21.7% to the ICU with mechanical ventilation requirement (ICU-MV). 28-day mortality was 34.9%; and was 26.3%, 30.1% and 61.4% for ward, ICU and ICU-MV MESHD patients. Convalescent plasma SERO was administered to 868 patients (24.6%); their 28-day mortality was significantly lower (25.5% vs. 38.0%, p<0.001). No major adverse effects occurred. Logistic regression analysis identified age TRANS, ICU admission with and without MV requirement, diabetes MESHD and preexistent cardiovascular disease MESHD as independent predictors of 28-day mortality, whereas convalescent plasma SERO administration acted as a protective factor. Conclusions Our study suggests that the administration of convalescent plasma SERO in COVID-19 MESHD pneumonia HP pneumonia MESHD admitted to the hospital might be associated with decreased mortality.

    The Importance of SARS-CoV-2 N-Ag Serodiagnostics for the Management of COVID-19 MESHD Pneumonia HP in Hospital Settings

    Authors: Yuri S. Lebedin; Olga V. Lyang; Anaida G. Galstyan; Anna V. Panteleeva; Vsevolod V. Belousov; Denis Rebrikov

    doi:10.21203/rs.3.rs-88799/v1 Date: 2020-10-06 Source: ResearchSquare

    We report evaluation of the SARS-CoV-2 nucleocapsid antigen (N-Ag) and respective antibodies SERO as diagnostic markers in pneumonia HP pneumonia MESHD patients. The study was conducted at the height of COVID-19 MESHD pandemic in Moscow, Russia. It included 425 emergency patients with clinical signs of COVID-19 MESHD pneumonia MESHD pneumonia HP, of which 280 (66%) were positive for either serum SERO N-Ag and/or its respective antibodies SERO. We demonstrate the total prevalence SERO of N-Ag seroconversion in SARS-CoV-2-associated pneumonia HP pneumonia MESHD patients within 3-5 days after hospital admission. The results indicate high feasibility of SARS-CoV-2 serodiagnostics in emergency patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.